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Dairy and egg products constitute an important part of Western diets as they represent an excellent source
of high-quality proteins, vitamins, minerals and fats. Dairy and egg products are highly diverse and their associations
with a range of nutritional and health outcomes are therefore heterogeneous. Such associations are also often weak
or debated due to the difficulty in establishing correct assessments of dietary intake. Therefore, in order to better
characterize associations between the consumption of these foods and health outcomes, it is important to identify
reliable biomarkers of their intake. Biomarkers of food intake (BFIs) provide an accurate measure of intake, which is
independent of the memory and sincerity of the subjects as well as of their knowledge about the consumed foods.
We have, therefore, conducted a systematic search of the scientific literature to evaluate the current status of potential
BFIs for dairy products and BFIs for egg products commonly consumed in Europe. Strikingly, only a limited number of
compounds have been reported as markers for the intake of these products and none of them have been sufficiently
validated. A series of challenges hinders the identification and validation of BFI for dairy and egg products, in particular,
the heterogeneous composition of these foods and the lack of specificity of the markers identified so far. Further studies
are, therefore, necessary to validate these compounds and to discover new candidate BFIs. Untargeted metabolomic
strategies may allow the identification of novel biomarkers, which, when taken separately or in combination,
could be used to assess the intake of dairy and egg products.
Keywords: Biomarkers of food intake, Food exposure markers, Dietary assessment, Dairy, Milk, Cheese, Yogurt,
Whey, Casein, EggsBackground
The assessment of dietary intake with food frequency
questionnaires, food diaries and 24 h recall methods is
an important element of nutritional research as it allows
to link the dietary behaviour of subjects enrolled in nu-
tritional studies to their health status [1]. The applica-
tion of these self-reporting tools is, however, limited by
their subjective nature. Biomarkers of food intake (BFIs),
on the other hand, belong to the class of dietary and
health biomarkers and measure the intake of specific
food groups, foods, or food components and can be used
to estimate recent or average intake of these entities [2].* Correspondence: guy.vergeres@agroscope.admin.ch
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(http://creativecommons.org/publicdomain/zeCombining the more classical assessment of dietary intake
with robust, validated BFIs is therefore an obvious step to-
wards improved assessments in nutritional studies [2–6].
The Joint Programming Initiative ‘A Healthy Diet for a
Healthy Life’ (JPI-HDHL) Food Biomarker Alliance
(FoodBAll) has developed a strategy [7, 8] and a meth-
odology to define [2], identify [9] and validate [10] BFIs
(http://foodmetabolome.org). In particular, FoodBAll
aims at mapping the currently known or suggested BFIs
for a range of foods across all major food groups, asses-
sing their strengths and weaknesses and prioritizing the
work needed to identify new biomarkers and to validate
previous candidates, thereby providing much better tools
for future studies in nutrition and health [7, 8]. Among
these foods, foods of animal origin constitute a predom-
inant part of Western diets [11]. Foods of animal origin
can be primarily divided into (i) meat (mammals andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Münger et al. Genes & Nutrition  (2018) 13:26 Page 2 of 18birds) and meat products, (ii) fish, seafood and terrestrial
animals other than mammals and birds, (iii) milk and
dairy products, (iv) eggs and egg products and (v) animal
fats and their primary derivatives [11, 12]. These foods
are highly diverse in their characteristics (chemical com-
position, texture…), even for foods within each of these
subcategories, rendering the analysis of their associations
with nutritional and health outcomes difficult. A strategy
taking into account this diversity is therefore necessary
in order to identify BFIs that can ultimately support nu-
tritional policies aimed at public health and disease pre-
vention. This article focuses on BFIs for dairy products
and BFIs for egg products. It is the first of two articles of
the FoodBAll consortium in which potential BFIs for
foods of animal origin commonly consumed in Europe
are reviewed; the second article on fish and meat intake
will be published separately.
Dairy products constitute a heterogeneous food group,
which includes milk and milk proteins (casein and whey),
fermented non-solid dairy products (sour cream, butter-
milk, quark, kefir and yogurt), butter and cheese. The asso-
ciation of dairy products intake with disease outcomes is
debated and often weak, except possibly for protection
against osteoporosis [13]. However, the weak associations
could very well be due to the heterogeneity of the compos-
ition of these products. Dairy products have been under
criticism regarding their impact on health due to their high
content in saturated fatty acids [14], salt (cheese) [15] and
added sugar (e.g. yogurt) [16]. In particular, the relatively
high intake of saturated fats that accompanies dairy intake
has been speculated to result in increased cholesterol levels
[17]. However, cheese intake seems to lower cholesterol
compared to an equal amount of fat from butter indicating
that other compounds in fermented dairy products may
provide beneficial actions beyond those expected solely
from the nutritional composition of these products [18].
On the other hand, a recent review of 52 clinical studies
investigating the influence of dairy products on inflam-
matory markers concluded that dairy products have
anti-inflammatory properties, particularly for persons
suffering from metabolic diseases. This review provided
evidence for an anti-inflammatory activity of both low-
and high-fat dairy products, as well as for fermented
dairy products [19]. Given the large variety of dairy
products, there is a clear need to identify and validate
specific BFIs that could discriminate between different
dietary sources of these products.
Eggs and egg products represent another important
group of foods of animal origin. Eggs, most commonly
from hens, are a rich source of proteins, hence of amino
acids, and several essential nutrients, particularly vitamin
D, vitamin B12, vitamin A, selenium and choline. Eggs
are also rich in cholesterol, but there is no strong associ-
ation between egg intake and risk of CVD [20]. However,since eggs are hidden in many foods, associations be-
tween their consumption and health effects or diseases
are difficult to establish and, therefore, remain uncertain.
This fact points out the crucial need to find reliable bio-
markers for egg intake.
In this manuscript, the most promising BFIs for
dairy products and BFIs for egg products will be
reviewed and evaluated for their suitability as bio-
markers of intake, according to the validation scheme
proposed by FoodBAll [10].
Methods
Selection of food groups
In order to obtain a good coverage of the foods of ani-
mal origin consumed in Europe, the three main classes
of animal-derived products were taken into account:
meat, including fish and seafood, dairy products and
eggs. In the present review, we report the results from a
systematic literature search for dairy products and eggs.
Dairy products were subdivided into seven categories:
milk, butter, cheese, yogurt, other fermented non-solid
products, as well as whey and casein proteins. Therefore,
including eggs, a total of eight food groups were
reviewed for their respective biomarkers of intake.
Primary literature search
The article selection, reviewing and reporting process made
use of the methodology previously proposed from the
FoodBAll consortium to carry out an extensive, systematic
literature search and evaluation of BFIs [9]. In brief, original
research papers and reviews were searched in at least two
databases, including PubMed, Scopus and ISI Web of
Knowledge, using combinations of the grouped search
terms (biomarker* OR marker* OR metabolite* OR bioki-
netics OR biotransformation) AND (trial OR experiment
OR study OR intervention) AND (human* OR men OR
women OR patient* OR volunteer* OR participant*) AND
(urine OR plasma OR serum OR blood OR excretion)
AND (intake OR meal OR diet OR ingestion OR consump-
tion OR eating OR drink* OR administration), as reported
in Additional file 1: Table S1, together with specific
keywords related to each animal-derived food group
(Additional file 1: Table S2). The default search fields for
each of the databases were [All Fields] for PubMed, [Article
Title/ Abstract/ Keywords] for Scopus and [Topic] for ISI
Web of Science, respectively. In the case of the search for
“milk”, the field [Abstract/title] was used in the PubMed
database to focus the search and reduce the number of ir-
relevant results. The literature search was conducted in No-
vember 2015. The search for dairy products, milk, cheese,
milk protein and non-solid fermented product was updated
in March 2017. In 2016, FoodBAll has initiated a series of
well-defined standardized short-term interventions studies
covering a range of fourteen foods [7], among these are
Münger et al. Genes & Nutrition  (2018) 13:26 Page 3 of 18milk and cheese [21, 22]. The data resulting from these
studies has only been partially analysed and published and
will therefore be evaluated at a later stage.
The search was limited to papers in the English language,
while no restriction was applied for the publication date.
The research papers identifying or using potential bio-
markers of intake for the foods of animal origin were
selected from the initial list of retrieved references by one
or more skilled researchers in a process outlined in
Additional file 2: Figure S1. The papers obtained from the
search in different databases were merged and filtered for
duplicates. Subsequently, papers were screened based on
title and abstract. The selected papers were then retrieved
and assessed for eligibility based on the contents of the en-
tire manuscript. Additional papers were identified from ref-
erence lists in these papers and from reviews or book
chapters identified through the search. The result was a list
of compounds potentially relevant as biomarkers for the
food group and corresponding references (Table 1 and
Additional file 1: Tables S3–S9).
Exclusion criteria
Exclusion criteria were specific for each food searched and
are reported in Additional file 2: Figure S1. In general, pa-
pers were excluded if they investigated the effect on hu-
man physiology of the food considered, the presence or
effect of toxicants, if they referred to unspecific markers
or if they were based on in vitro or animal models.
BFIs identification and classification
A second search step was used to evaluate the apparent
specificity of the markers in the list. The compound da-
tabases HMDB [23] and FooDB (//foodb.ca) were used
for the first evaluation of marker specificity. If the
marker was not specific for a single food group, its rela-
tion to any foods outside the animal-derived food groups
was documented. In the latter case, the compound was
omitted from the list for the next search. The remaining
list of potential biomarkers was used for a second litera-
ture search in the three bibliographic databases used for
the primary search in order to identify other foods con-
taining the potential biomarkers, or their precursors, as
well as foods otherwise associated with these com-
pounds. For the second web-based literature search, the
“marker name” was used as a keyword, together with
AND (biomarker* OR marker* OR metabolite* OR bio-
kinetics OR biotransformation). Further filters, such as
(urine OR plasma OR serum OR blood OR excretion)
AND (intake OR meal OR diet OR ingestion OR con-
sumption OR eating OR drink* OR administration)
AND (human* OR men OR women OR patient* OR vol-
unteer* OR participant* OR subject*), were added based
on the results obtained. Again, markers related to foods
of non-animal origin were deleted from the list.Potentially specific markers for each animal-derived food
group or for several combined foods of animal origin are
listed in Table 1, together with information about the
study designs of the papers reporting their use. Due to the
large number of studies, which suggested C15 and C17 as
markers for dairy intake, only intervention studies were
listed in Table 1 for these two metabolites. For all other
markers identified, observational and interventional stud-
ies were considered in Table 1. The full list of studies for
each food category is available in Additional file 1: Tables
S3–S9. At the end of this selection process, the strength
and weakness of each compound was evaluated and the
most promising biomarkers were scored to assess their
validity as BFIs according to the system reported below.
Marker validation assessment
In order to further assess the validity of the biomarker
candidates, a set of consensus evaluation criteria, from
the FoodBAll consortium, was employed [10]. In par-
ticular, the usefulness of each marker was assessed by
answering a set of simple questions (Additional file 1:
Table S10), which reflect the analytical and biological
criteria that the proposed biomarker should fulfil in
order to be considered valid. Possible answers were Y
(yes, the criterion is fulfilled for at least some use of the
biomarker), N (no, the criterion has been investigated
but it was not fulfilled), or U (uncertain, the criterion
has not been investigated or data is not available). The
potential markers were scored for chemical and bio-
logical plausibility (question 1), dose-response relation-
ship, including saturation levels (question 2) and
time-response after acute and repeated intake (question
3). The markers were further evaluated for their robust-
ness in complex diets or real exposure situation (ques-
tion 4) and reliability (question 5), that is the
concordance with other measures of intake for the food
or food group in question (such as other existing vali-
dated biomarkers or dietary instruments). The analytical
aspects of each BFI were investigated through an evalu-
ation of their chemical stability (question 6), their analyt-
ical performance (question 7) and reproducibility in
different laboratories (question 8). This approach was
applied to obtain an overview of the current level of val-
idation of candidate BFIs and highlight which additional
studies are needed to provide full validation of each can-
didate biomarker of animal-based foods [10].
Results and discussion
Biomarker of dairy products
After removal of duplicates, the original papers identify-
ing or using potential biomarkers of intake for the differ-
ent dairy products were selected from the list of
retrieved references by two skilled researchers, following
the process outlined in Additional file 2: Figure S1. In
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Münger et al. Genes & Nutrition  (2018) 13:26 Page 5 of 18total, 1023, 730, 271, 196, 280, 329 and 153 publications
were found using the above-defined search criteria for
dairy products, milk, butter and cheese, yogurt, casein
and whey, respectively. These papers were further
screened for relevant markers. In the end, after the
web-based literature search and the examination of the
reference lists, only 23 papers contained relevant infor-
mation about putative markers for dairy intake, 6 for
milk, 3 for butter, 2 for cheese, 7 for yogurt, 3 for casein
and 6 for whey intake. The search for non-solid fermen-
ted dairy products did not provide any relevant papers.
Additional details regarding these studies are reported in
Additional file 1: Tables S4–S9. The most promising
candidates were selected and the validation criteria de-
scribed by Dragsted et al. [10] were employed in each
case (Table 2). In the following chapters, the characteris-
tics of these candidate makers are presented.
Dairy products in general
We found that most studies focused on lipids when
assessing biomarkers of dairy product intake. Based on
observational data, the majority of these studies applied
a targeted approach for fatty acid analysis using gasTable 2 Validation scheme for candidate intake biomarkers of dairy
Table S10. Possible answers are Y (yes, the criterion is fulfilled for at
investigated but it was not fulfilled), or U (uncertain, the criterion ha
are based on the criteria of Dragsted et al. [10]
Food item Metabolites HMDB
Dairy fat/dairy products C15:0 HMDB0
C17:0 HMDB0
C17:1 HMDB0
Dairy products Myristoyl-sphingomyelin SM(d18:1/14:0) NA
Galactonate HMDB0
Butter Methyl palmitate HMDB0
Cheese Isovalerylglutamic acid HMDB0
Isovalerylglycine HMDB0
Tiglylglycine HMDB0
Isobutyrylglycine HMDB0
Whey protein hydrolysed Cyclo (Phe-Val) NA
Cyclo (Ile-Val)/ Cyclo (Leu-Val) NA
Cyclo (Ala-Ile) NA
pGlu-Pro NA
pGlu-Leu NA
pGlu-Val NA
Whey protein γ -glutamyl-leucine HMDB0
γ-glutamyl-valine HMDB0
γ-glutamyl-methionine HMDB0
Casein Proline-proline HMDB0
Isoleucine-proline HMDB0chromatography (GC) in order to evaluate the potential
of two odd-chain fatty acids, pentadecanoic acid (C15:0)
and heptadecanoic acid (C17:0), as biomarkers of dairy
products or dairy fat [24–39]. The first study evaluating
ruminant fatty acids as biomarkers for dairy fat intake
based on dietary assessment showed that the content of
C15:0 as well as C17:0 in adipose tissue might serve as a
valid marker for long-term intake [40].
The high correlation between the levels of C15:0 in
adipose tissue and dairy fat intake has been confirmed
by subsequent studies [25–28]. Compared to adipose tis-
sue, the concentration of C15:0 in blood lipids might be
an equally good marker even though the correlation
values were somewhat lower. A positive correlation be-
tween dairy fat intake and C15:0 in serum cholesterol es-
ters has been observed in several studies [24, 25, 28].
Also, C15:0 in serum cholesterol esters has been associ-
ated with dairy product consumption in general [36]. An
even greater number of observational studies has shown
a positive association between C15:0 in phospholipids in
serum or plasma and the intake of dairy fat [24, 25, 27,
35], dairy products [30, 35, 41], whole-fat dairy products
[31, 42] and low-fat dairy products [42]. However,products. The questions Q1-Q8 are reported in Additional file 1:
least some use of the biomarker), N (no, the criterion has been
s not been investigated or data is not available). The questions
Biofluid Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8
000826 Blood plasma/serum Y U N Y Y U Y Y
002259 Blood plasma/serum Y U N Y Y U Y Y
060038 Blood serum Y U N Y U U Y N
Blood serum Y U N Y U U U N
000565 Y U N Y U U U N
061859 Blood serum Y U N Y U U U N
000726 Urine Y U N Y U U U N
000678 Urine Y U N Y U U U N
000959 Urine Y U N Y U U U N
000730 Urine Y U N Y U U U N
Blood plasma N U Y U U U U U
Blood plasma N U Y U U U U U
Blood plasma N U Y U U U U U
Blood plasma N U Y U U U U U
Blood plasma N U Y U U U U U
Blood plasma N U Y U U U U U
011171 Blood plasma U U Y U U U U U
011172 Blood plasma U U Y U U U U U
034367 Blood plasma U U Y U U U U U
011180 Blood plasma U U Y N U U U U
011174 Blood plasma U U Y N U U U U
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tween dairy fat intake and C15:0 in serum phospholipids
or in free fatty acids but reported high correlation with
C15:0 in cholesterol esters and serum triacylglycerols.
Positive correlations in observational studies have also
been demonstrated for C15:0 with total serum or plasma
lipids and dairy fat intake [26, 29], as well as with dairy
product intake [33, 38, 39]. Positive correlations were
also found between C15:0 in dried blood spots and the
intake of total, high-fat and low-fat dairy products, the
correlation with high-fat dairy products being the stron-
gest [37]. None of these studies used untargeted metabo-
lomics except for the study by Nestel et al. [41]. In
addition to several complex lipids identified as putative
markers, C15:0 in phospholipids and in lysophospho-
sphatidylcholine showed a significant association with
the number of dairy servings. The growing body of evi-
dence from observational studies to use C15:0 as a bio-
marker of dairy fat or dairy products intake has been
complemented by the outcomes of recent intervention
studies. In another study, increasing dairy intake resulted
in a small increase in plasma C15:0 levels whereas de-
creasing dairy intake was not associated with a change
in the level of C15:0. In contrast, the replacement of
full-fat dairy foods by reduced-fat or low-fat products
was associated with decreased levels of serum C15:0, in-
dicating that blood level of C15:0 is sensitive to changes
in the absolute intake of dairy fat.
The effect of dairy fat on blood lipids upon short-term
intake was assessed in 124 healthy volunteers consuming
a daily three servings of dairy products or control prod-
ucts [39]. After 4 weeks, the fatty acid profiles, as analysed
by targeted GC-FID, revealed that the plasma levels of
C15:0 were significantly higher when compared to the in-
take of non-dairy control products. Postprandial effects
were investigated by comparing plasma phospholipids
profiles using a LC-MS lipidomics approach, which re-
vealed that phosphatidylcholine containing C15:0 showed
a significantly larger plasma increase after the dairy-based
meal compared to the soy meal.
Several observational studies investigating the associ-
ation between dairy intake and C15:0 in blood also in-
cluded C17:0 analyses. Some of these studies showed that
C17:0 in cholesterol esters [25], C17:0 in phospholipids
[25, 27, 35] and C17:0 in lysophosphatidylcholine [41]
were associated with dairy fat intake. Controversially, the
study by Smedman et al. [24] did not reveal a correlation
of serum C17:0 phospholipids to milk fat intake, while
Brevik et al. [26] even reported an inverse association be-
tween serum C17:0 and dairy fat intake. The correlation
factors between plasma C17:0 and dairy fat and dairy
products intake were consistently lower when compared
to C15:0 or even to trans16:1n-7 [29]. Albani et al. [37] re-
ported a positive correlation of C17:0 in whole bloodsamples with the intake of total, high-fat and low-fat dairy
products. The correlation was however lower in compari-
son to C15:0. Interestingly, a cross-sectional study includ-
ing 2380 participants and using targeted metabolomics
proposed serum lysophosphatidylcholine C17:0 as a spe-
cific marker of dietary pattern consisting of high intake of
high-fat dairy and butter combined with a low margarine
intake [43]. The intervention studies devoted to C15:0 in
the former paragraphs also showed an effect of dairy prod-
ucts on serum C17:0 phopshatidylcholine levels during a
4 h postprandial period [44], on plasma levels of C17:0
after 4 weeks of daily intake of three dairy servings [39] as
well as after an increased dairy intake [32]. However, the
levels of serum C17:0 were not affected by replacing
full-fat dairy with low-fat dairy products [34]. Overall,
C17:0 seems to be a less sensitive marker of dairy intake
in comparison to C15:0.
Finally, a cross-sectional study associating phospho-
lipid fatty acids with food intake reported that the sum
of plasma C15:0 and C17:0 phospholipids was not asso-
ciated with dairy products intake at the population level
but an association was found at the individual level. This
finding suggests that the combination of several nutri-
ents with an individualization of data analysis may repre-
sent promising strategies for the identification of specific
markers of food intake.
Nevertheless, due to inconsistent outcomes, it re-
mains unclear if the use of odd-chain fatty acids as bio-
markers for dairy intake is limited to dairy fat intake
only or to the intake of dairy products in general. In
addition, a randomized, double-blind crossover study in
16 healthy individuals showed that supplementation
with inulin or propionate for 7 days significantly in-
creased pentadecanoic acid and heptadecanoic acid
[45], indicating that the endogenous production of
these molecules may be a confounder for their use as
BFIs. Moreover, concern has been expressed regarding
the use of odd-chain fatty acids as markers of dairy
products as these molecules also occur in certain types
of fish and in meat [46, 47]. Indeed, Saadatian-Elhani
et al. [48] reported a strong positive correlation be-
tween the total intake of fish and plasma C17:0 whereas
there was no correlation to dairy product intake at the
population level. On the other hand, a metabolic ana-
lysis by Floegel et al. [43] found that the intake of dairy
products, but not the intake of fish, was associated with
lysophosphatidylcholine C17:0. Also, in other studies
investigating both fish and dairy products, no correl-
ation between odd-chain fatty acids and fish intake was
reported [35, 36]. In conclusion, in populations con-
suming high amounts of fish, the intake of C15:0 and
C17:0 through fish should not be neglected in studies
targeting markers for the intake of dairy products in
order to avoid misleading conclusions [46].
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fatty acids were also proposed as specific biomarkers of
dairy intake. Heptadecaenoic acid (C17:1) has been found
to strongly correlate with the total intake of dairy products
in one study [28] but was not investigated in any further
studies. Apart from odd-chain fatty acids, other ruminant
fatty acids correlate with dairy intake. Trans-palmitoleic
acid (trans-16:1n-7) in plasma total lipids correlates well
with the intake of dairy fat [29] whereas plasma
trans-16:1n-7 in phospholipids is associated with full-fat
dairy intake [41, 42], but not with low-fat dairy intake [42].
Abdullah et al. [39] reported no effect on trans-16:1n-7
levels after 4 weeks’ intake of low-fat products. Erythrocyte
trans-18:1 isomers were significantly correlated with total
dairy consumption [49, 50]. However, some of these trans--
fatty acids were also found in other foods and may thus be
excluded from the list of potential markers of dairy intake.
Metabolites present in other foods include trans-16:1n-7,
which occurs in other ruminant-based foods, in particular,
meat, at significant levels [51]. This compound can even
be endogenously synthesized by humans from dietary
trans-18:1 [52]. Trans-18:1 isomers may also derive from
multiple foods produced with partially hydrogenated vege-
table oils [51].
Phytanic acid is another fatty acid found in ruminant
products. In a cross-sectional study, the strongest deter-
minant of plasma phytanic acid concentration appeared
to be dairy fat intake but a positive correlation was also
found for ruminant meat [53]. Due to the lack of inter-
vention studies and the use of metabolomics methods, it
remains questionable if certain trans-fatty acids or phy-
tanic acid are specific enough to be used as dairy
markers or if they may rather serve as ruminant food
markers. A correlation to the intake of dairy products or
dairy fat has also been shown for myristic acid (C14:0)
[25, 27, 32, 35, 36, 42]. However, this fatty acid occurs in
most of the animal and vegetable fats and, thus, remains
unspecific. Other unspecific fatty acids, which were
shown to correlate to the intake of dairy products are
C18:0 and C18:1n-9 [36], as well as C18:3n-6, C22:1n-9
and C22:5n-3 [39]. Other metabolites associated with
dairy consumption have been identified but were not yet
extensively studied. Nestel et al. [41] demonstrated that
phospholipid C18:1n-7 (vaccenic acid) correlated with
the number of full-fat dairy servings while two molecu-
lar forms of lyso-platelet-activating factor (C20:0 and
C22:1) directly correlated with the number of dairy serv-
ings. Phosphatidylcholines C29:0, C31:0, C35:1, C28:0,
C30:0, C32:0 and C32:1 showed a significantly larger in-
crease in the postprandial period after the dairy meal
compared to the soy meal possibly being indicative for
dairy consumption [44]. More studies validating and
confirming these metabolites for dairy intake are, how-
ever, required.Another study showed that plasma trimethylamine-
N-oxide (TMAO), a metabolite deriving from choline,
was positively associated with milk and dairy food con-
sumption [54]. Controversially, a 2-week intake of diets
high in cheese and high in milk even decreased urinary
TMAO levels compared to the control diet as reported
by Zheng [55]. These authors suggest that cheese and
milk modify the gut microbiota thus decreasing TMAO
formation. Also, other experiments demonstrated that
plasma TMAO was associated with several foods including
egg intake [56], whereas urinary TMAO was associated
with salmon intake [57]. Of note, TMAO is particularly in-
teresting with regards to current discussions on its potential
use as a prognostic factor for heart failure [58].
Based on an untargeted multi-platform—omics ap-
proach, a most recent study observed a positive correl-
ation between serum myristoyl-sphingomyelin SM(d18:1/
14:0), as well as galactonate and the intake of dairy prod-
ucts in fasting samples from nested case-control studies
[59]. These metabolites represent two novel candidate
markers and both deserve more investigation. Sphingo-
myelin is a component of the milk-fat globule and makes
up about one third of total milk phospholipids [60], show-
ing high potential to be specific to the intake of
fat-containing dairy products. SM(d18:1/14:0) has been
shown to be postprandially increased after a dairy meal
and was decreased after a soy meal [61]. However, other
animal-derived foods (meat, fish and egg) are also sources
of sphingolipids [62], so that levels of SM(d18:1/14:0) in-
fluenced by other foods cannot be ruled at this point. On
the other hand, galactonate derives from galactose metab-
olism and may possibly only be formed after ingestion of
dairy products still containing high levels of galactose or
lactose, respectively, thus non-fermented products.
Milk
Milk is a highly complex food providing essential macro-
nutrients, vitamins, trace elements and minerals as well as
many bioactive components. These may act synergistically
to modulate metabolic and immunomodulatory processes,
which are important for the maintenance of human health
[61]. Pasteurized full-fat milk is mainly composed of water,
followed by lactose, fat and proteins [63]. However, the
exact composition of milk depends on several factors in-
cluding feeding practices, breed, age and health status of
the animals [61]. Technological treatments and storage
conditions introduce further variations in macro- and
micronutrient concentrations. As milk in its raw or
heat-processed form is the starting material for a broad
range of products, the challenge in identifying a marker
compound specific for its intake is that it should not be
present after intake of any other dairy product. Even
though the health benefits of milk have been well docu-
mented, investigations on metabolites in human biofluids
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on dairy products in general.
First, three intervention studies that have used milk as a
control or a test product are considered. The studies were
conducted in children (high milk or high meat diet during
7 days) [64], in patients suffering from irritable bowel syn-
drome (probiotic yogurt or non-fermented acidified milk
during 8 weeks) [65, 66] or in healthy adults (diet high in
milk, high in cheese, or a control diet for 14 days) [55].
The potential biomarkers of milk intake identified in-
cluded serum SFCA [64], L-lactate, 3-hydroxybutyrate,
glutamine, proline, creatine/creatinine, aspartic acid [65,
66], urinary citrate and faecal glycerol [55].
Then, two observational studies treated milk as a separ-
ate variable by not including it in the general category of
dairy products. Using food frequency questionnaires from
502 men and women aged 55–74 years, the first study
could associate serum homostachydrine (also known as
pipecolic acid betaine) with milk intake [67]. The second
study could associate the intake of full-fat cow milk in
toddlers with serum pentadecanoic acid C15:0, palmitic
acid C16:0 and conjugated linoleic acid (CLA) [68].
However, the potential of using the above-mentioned
metabolites as markers of milk intake remains elusive
because of their lack of specificity. Several are involved
in endogenous, biochemical reactions in humans, such
as glycerol, which is released during the breakdown of
triacylglycerols and phospholipids, citrate, which is
formed in the tricarboxylic acid cycle, or free amino
acids. Others can be influenced by dietary components
other than milk. Blood SCFA can be influenced by co-
lonic fermentation of fibres from cereals [69, 70], lactate
and 3-hydroxybutyrate have been observed after the in-
gestion of wheat bran [71] and decaffeinated green tea
extract [72], while C16:0 is one of the most common sat-
urated fatty acids in animal and plant-based foods. As
previously described, C15:0 may possibly serve as a bio-
marker of dairy fat or dairy products but it is not spe-
cific for milk. Homostachydrine is a plant metabolite
occurring in, for example, alfalfa and citrus fruits [73].
The concentration of this specific compound in humans
having ingested dairy products may thus depend on its
content in milk, which in turn may depend on the feed
supplied to the cattle. CLA, which can be formed by ru-
minal bacteria from unsaturated fatty acids, is mainly
found in ruminant foods such as meat and milk, milk fat
being dominated by cis-9, trans-11 CLA isomers. It
might thus be a marker for ruminant foods, which
would need validation against other CLA-containing
foods of non-ruminant sources, for instance, egg. None-
theless, the synthesis of CLA is not restricted to ruminal
microbial activity as it can also be synthesized in
humans through desaturation of vaccenic acid [74],
which is a fatty acid also present in milk.Finally, the studies mentioned here differ in the use of
semi-skimmed [55, 65, 66] or skimmed milk [64], and
information on heat treatment has only been supplied
by the studies from Pedersen et al. [65, 66] who adminis-
tered high-pasteurized milk. Such technological treat-
ments have to be taken into account when evaluating
the validity of potential biomarkers of intake.
Butter
Butter is a traditional dairy food being consumed world-
wide, either pure in the form of a spread or processed in
pastes or bakery products, as well as for refinement of
foods and dishes. Besides water, proteins, lactose, lactic
acid, vitamins and minerals, butter consists of approx.
80% of fat (mainly triacylglycerols), which is character-
ized by a broad fatty acid distribution ranging from
short-, middle- to long-chain saturated and unsaturated
molecules [63, 75].
Hjerpsted et al. [76] reported a 6-week intervention
study applying a randomized crossover design investigat-
ing the effects of butter (control) and cheese (interven-
tion) on urinary metabolites. Urine samples were analysed
using an untargeted LC-MS approach. By applying univar-
iate statistics and comparing the urine metabolome after
daily cheese and butter consumption, seven metabolites
were related to the intake of butter. However, these me-
tabolites were only characterized by their mass-to-charge
ratio in either positive or negative mode and their identifi-
cation remains unknown.
Two recent observational studies investigated metabo-
lites attributed to the intake of butter based on food
frequency questionnaires [43, 67]. A cross-sectional
study assessing associations between serum metabolites
and habitual diet analysed by a targeted approach re-
vealed that a diet with high butter but low margarine in-
take was associated with the presence in serum of
acylcarnitines, acyl-alkyl-phosphatidylcholines, lysopho-
sphatidylcholines and hydroxy-sphingomyelins [43].
Monounsaturated diacyl-phosphatidylcholines (C36:1,
C28:1 and C34:1) were associated with high butter and
sauce intake, whereas acyl-alkyl-phosphatidylcholines
(C34:0, C36:1, C34:1 and C30:0) were associated with
high intake of butter as well as red meat and high-fat
dairy products. Lysophosphatidylcholines were associ-
ated with butter but also high-fat dairy and non-dairy
sweet spreads, while sphingomyelin was associated with
butter but also garlic and coffee intake. Only saturated
acylcarnitines C9:0, C16:0 and C18:0 may have the po-
tential to specifically serve as biomarkers for a diet with
high butter intake. High levels of these acylcarnitines
can be explained by the fatty acids provided through the
intake of butter, whose composition is dominated by
C16:0 and C18:0. However, the concentration of total
acylcarnitines in blood is influenced by the dynamics of
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fasting period or exercise (catabolic state) due to ele-
vated beta-oxidation of fatty acids in order to provide
energy [77]. Moreover, acylcarnitine C16:0 is also ele-
vated in the metabolic profile of meat consumers [78].
In a nested case-control study with cases suffering
from colorectal cancer, correlations between metabolites
and diet were assessed [67]. Three metabolites positively
correlated with butter intake, namely methyl palmitate,
pentadecanoic acid (C15:0) and 10-undecenoate. How-
ever, no differences in the association between the three
molecules and dietary intake were observed by disease
status, underlying the robustness of these putative
markers as markers of dietary intake rather than markers
of the health status. Methyl palmitate is a natural fatty
acid methyl ester, which has been reported to occur in
raw milk [79] and has not yet been found to be influ-
enced by other dietary factors. On the other hand, al-
though C15:0 was associated with butter intake, this
molecule should rather be discussed as a marker for the
intake of high-fat dairy products in general as discussed
in the previous sections. Finally, 10-undecenoate is a
monounsaturated medium-chain fatty acid with antifun-
gal activity obtained by pyrolysis from castor oil [80],
which had not been previously associated with dairy
products; thus, its link to butter intake remains unclear.
Cheese
Cheese is mostly composed of proteins, fat and water.
Fermentation with different species of lactic acid bac-
teria but also technological processes have led to a large
variety of cheese types. Compounds derived from the
fermentation process possess the greatest potential as
biomarkers of cheese intake. However, the occurrence
and concentration of such metabolites vary depending
on many factors such as selection of the starter culture
and ripening stage. The major challenge in the identifi-
cation of biomarkers of cheese intake is the identifica-
tion of a general marker representing the huge variety of
cheese types.
Only few studies have been published on the identifica-
tion of biomarkers of cheese intake. In a 6-week interven-
tion study, based on untargeted LC-MS analyses, a high
number of discriminating metabolites for cheese intake
were identified when compared to butter intake [76].
Among these were urinary indoxyl sulfate, xanthurenic
acid, tyramine sulfate, 4-hydroxyphenylacetic acid, isova-
lerylglutamic acid, isovalerylglycine, tiglylglycine and iso-
butyrylglycine. Indoxyl sulfate is synthesized from indole
in the liver, a metabolite from tryptophan formed by the
gut microbiota. Xanthurenic acid, formed via the kynure-
nine pathway, is another metabolite derived from trypto-
phan catabolism. The release of tryptophan during the
cheese making process is attributed to the proteolyticactivity of bacterial enzymes. However, increased levels of
urine and plasma indoxyl sulfate have also been observed
after the ingestion of a high-protein diet based on
non-fermented milk proteins [81]. Urinary xanthurenic acid
has been found to be a discriminating marker after cocoa
powder with milk consumption [82]. Tyramine sulfate and
4-hydroxyphenylacetic acid derive from tyramine, an un-
desirable biogenic amine, which is formed by the microbial
decarboxylation of free tyrosine during cheese ripening.
Due to the detrimental effect of biogenic amines on health,
their levels are kept as low as possible by optimizing
technological processes. Thus, the potential use of
tyramine-derived metabolites as a general biomarker of
cheese intake is inappropriate. Furthermore, biogenic amines
are not only restricted to cheese but also occur in fish and
other fermented foods [83]. Metabolites derived from bio-
genic amines might thus rather represent biomarkers of fer-
mented foods or as markers for quality issues during
production. The formation of 4-hydroxyphenylacetate, an-
other marker identified by Hjerpsted et al. [76], is also linked
to gut microbiota metabolism of phenolic compounds; its
levels in urine are changed after a vegetarian diet [84], wine
intake [85] and the consumption of green tea [86]. Isovaleryl-
glycine and tiglylglycine are metabolites derived from the
catabolism of leucine and isoleucine, respectively. Isobutyryl-
glycine might derive from isobutyric acid, an aroma com-
pound in cheese, or might be formed through valine
catabolism [76]. So far, the occurrence of acylglycines in
urine has not yet been linked to the consumption of other
foods and thus these molecules remain interesting as poten-
tial biomarkers for cheese intake.
In a second intervention study, 15 volunteers con-
sumed a diet high in semi-skimmed milk or cheese and
a control diet for 14 days [55]. Based on NMR metabolo-
mics analyses, cheese intake could be discriminated from
milk intake and the control diet by significantly in-
creased levels of urinary proline betaine and tyrosine.
Tyrosine concentration in cheese increases due to the
proteolytic activity of bacteria during processing and rip-
ening. The authors thus suggest using tyrosine and pro-
line betaine as exposure markers for cheese intake.
However, the urinary concentration of proline betaine is
significantly influenced by the consumption of citrus
fruits and is considered a valid biomarker for citrus fruit
intake [87–90]. On the other hand, tyrosine is a
non-essential amino acid and elevated levels of urinary
tyrosine have also been observed after cocoa consump-
tion [91]. Therefore, neither proline betaine nor tyrosine
is sufficiently specific as markers of cheese intake. In the
same study, the consumption of both cheese and milk
increased short-chain fatty acids (SCFA) when compared
to the control diet in faecal samples. Furthermore,
cheese intake was discriminated from milk intake by an
increase in faecal butyrate. These observations can be
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contained SFCAs in different concentrations, but also by a
more complex effect involving the metabolic activity of
the gut microbiota on ingested nutrients [55]. For in-
stance, butyrate levels in faeces are modified by the intake
of dietary fibres [70, 92]. Therefore, SCFAs cannot be con-
sidered as specific biomarkers for cheese intake.
In order to obtain validated biomarkers for cheese in-
take, more studies with a variety of cheese types are re-
quired and potential biomarkers of cheese intake need
to be validated against markers of intake of other fer-
mented foods rich in protein such as yogurt.
Fermented non-solid dairy products
The use of differently processed milk as starting material
(e.g. skimmed milk for quark, cream for sour cream,
etc.) in addition to differences in the fermentation
process (e.g. yeast fermentation in case of kefir) might
lead to the formation of biomarkers enabling the dis-
crimination of fermented non-solid dairy products from
yogurt and cheese. Primary search on biomarkers of the
intake of fermented non-solid products such as quark,
sour cream, kefir and buttermilk, however, did not iden-
tify relevant research publications. Evidently, there is a
lack of studies investigating intake biomarkers from fer-
mented dairy products other than yogurt and cheese.
Whey protein and casein
Whey protein (WP) is a mixture of globular proteins iso-
lated from whey, the liquid material obtained as a
by-product of cheese production. WP is typically re-
leased in the market as four major forms, which differ in
the production process and nutritional content, namely
concentrate (WC), isolate (WI), hydrolysate (WH) and
native whey: WC has a lower level of fat and cholesterol,
but higher level in carbohydrates and lactose, as well as
bioactive compounds; WI is processed to remove the fat
and lactose, but is lower in bioactive compounds; WH is
partially hydrolysed to facilitate the digestion and uptake
of amino acids derived from its proteins; native whey is
obtained from skim milk as a by-product of cheese pro-
duction [93–96]. Casein (CAS) refers to a group of
phosphoprotein (αS1, αS2, β, κ) commonly found in
mammalian milk. It represents the major component of
cheese, but it is also used as a food additive and protein
supplement. Compared to WP, casein is richer in argin-
ine, methionine, phenylalanine, proline and tyrosine [97,
98]. As for the other dairy products, different prepar-
ation methods, nutritional content and metabolic pro-
cessing by the human organism render the discovery of
candidate BFIs for such food products difficult.
When the intake of test drinks containing WP, WI,
WH and CAS was compared with those of other
carbohydrate-based drink or other protein sources, ageneral increase in plasma amino acids, urea and ammo-
nia was observed, which reflected the different amino acid
contents of the test proteins and the controls [99–101].
Furthermore, differences in postprandial peripheral amino
acids profile reflected the absorption and the first pass
metabolism [98, 102]. These results and the fact that
amino acids are unspecific and present in large amount in
many foods indicate that they cannot be used as a bio-
marker for the assessment of dairy protein intake.
A finding of the study of Stanstrup et al. [101] was the de-
tection of methionine oxidation products, methionine sulfox-
ide (MetSO) and its metabolites, N-phenylacetyl-methionine
(PAM) and N-phenylacetyl-methionine sulfoxide (PAMSO),
in plasma samples after WH intake. These results were ex-
plained by the elevated presence of MetSO already in the
powder material, as a result of the manufacturing process
that must have caused the oxidation of methionine to the
sulfoxide, while PAM and PAMSO could be generated en-
dogenously. Interestingly, in a subsequent study [98], the
same compounds were elevated after the CAS meal but not
after the WI meal. PAM and PAMSO were elevated in urine,
while PAM was also high in plasma. The authors ascribed
again such result to the meal composition and the manufac-
turing process, which produces MetSO. As MetSO has pre-
viously been quantified in milk protein products showing a
highly variable range of concentrations [103], such com-
pounds seem not to be reliable markers to monitor dairy
protein intake.
Another compound found in the two studies of
Stanstrup et al. [98, 101] was β-Asp-Leu, which was ele-
vated in plasma after the WH meal [101] as well as in
urine after CAS intake [98]. Of note, this compound
should not be present in dietary sources and should also
not enter the bloodstream, as β-aspartate has been found
to potently increase the immunogenicity of proteins in
pharmaceuticals [104].
More promising compounds were found by Stanstrup
et al. [98, 101] following the intake of the WP or CAS
meal. The identified metabolites were several cyclic di-
peptides and other amino acid metabolites, such as lin-
ear dipeptides or γ-glutamyl conjugates. The same cyclic
dipeptides were also identified in the powdered product
and could be classified into two groups, 2,5-diketopiper-
azines (DKPs) and pyroglutamyls. DKPs are side prod-
ucts of terminal peptide cleavage [105] created when the
free α-amine in one amino acid and the α-carboxylic
acid in the adjacent amino acid react to form a diketopi-
perazine ring. In particular, cyclo(Pro-Thr), cyclo(Phe--
Val), cyclo(Ala-Ile) and a compound which could be
either cyclo(Leu-Val) or cyclo(Ile-Val) showed a signifi-
cant increase in plasma after WH intake [101]. The pyr-
oglutamyls identified were pGlu-Pro, pGlu-Leu and
pGlu-Val. Such compounds are formed from glutamic
acid by reaction of the side-chain carboxylic acid with
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a 5-oxoproline ring structure and were higher in plasma,
as well, after the WH meal [101]. Interestingly, none of
these compounds have been discriminating for WI or
CAS in the second study [98] that suggests a specific
correlation with WH. Although these cyclic dipeptides
have already been found in several foods, such as cocoa
[106], roasted coffee [107], beef [108] and wheat gluten
[109], no other studies have investigated the presence of
such compounds in human body fluids.
In the same study, two markers for caseinoglycoma-
cropeptide (CGMP) intake were Pro-Pro and Ile-Pro
[101], which could derive from Ile-Pro-Pro, a tripeptide
found in CAS [110]. However, these dipeptides were not
confirmed for CAS in the second study [98], suggesting
that they may not be as robust as BFIs.
The levels of the intermediate metabolite γ-glutamyl-
leucine were also different between meals in both Stanstrup’s
studies [98, 101]. γ-glutamyl-leucine was higher after WI in-
take, but not after the casein-containing meals [98, 101]. The
authors suggested that this discrepancy could be directly re-
lated to the elevated levels of the parent amino acids in the
meal [98]. Although γ-glutamyl-leucine may reflect the pro-
teolytic breakdown products of larger proteins, it has also
been found in vegetables of the onion family (//foodb.ca).
Yogurt
Only few studies relate the consumption of yogurt to
compounds detected in biosamples. Among these, a ran-
domized crossover study comparing the effects of fresh
versus heated yogurt in males with and without lactose
malabsorption, reported an increase in plasma propion-
ate in men with lactose malabsorption after fresh yogurt
intake during 2 weeks, as well as a higher AUC of
plasma butyrate over 3 h after a load of fresh yogurt in
men without lactose malabsorption. However, no signifi-
cant change in plasma acetate was observed.
A parallel study evaluating the effect of a probiotic
yogurt on the serum metabolome of 61 patients with in-
flammatory bowel syndrome could not observe any
modification after an 8-week intake compared to a
non-fermented acidified milk [65]. In particular, an in-
crease in serum lactate and 3-hydroxybutyrate was ob-
served in both control and test groups, which raised the
question of the neutrality of the delivering vector (milk
in this case).
In an intervention crossover study, Fabian and col-
leagues [111] identified a significant increment of plasma
thiamine and riboflavin in young healthy women after a
4-week intervention with yogurt consumption. The au-
thors suggested that yogurt may contribute to the intake
of both vitamins, due to the capacity of some specific
strains of bacteria to synthesize B vitamins in fermented
milk products [111].Mohammad and co-workers [112] carried out a con-
trolled randomized clinical trial using yogurt with and
without Lactobacillus acidophilus fortification in children
for 6 weeks. They demonstrated that the consumption on
a daily basis of the supplemented yogurt significantly in-
creased the levels of plasma vitamin B12. Similarly, the re-
search held by Samuel et al. [113] pointed out that yogurt
intake was significantly associated with plasma vitamin
B12 status on a group of pregnant women with impaired
vitamin B12 status. The vitamin B12 status depends on
dietary intake, gut microbiota and the efficiency of its en-
terohepatic circulation [112]. Therefore, the positive asso-
ciation between yogurt intake and plasma levels of
vitamin B12 could be related to the probiotic function of
this food, since supplementation with probiotics has
shown to improve the vitamin B12 status [112, 114]. In
this field, it is important to point out that some intestinal
bacterial strains have the capability to synthesize vitamin
B12 in the small bowel [115]. Therefore, some bacteria
from the probiotics could have the capability to colonize
in the small bowel and produce vitamin B12 [114]. On the
other hand, some Lactobacilli strains can synthetize vita-
min B12 during the fermentation process, providing add-
itional amounts of this vitamin when these fermented
food are consuming [113].
As an alternative to circulating or faecal metabolites,
changes in the host microbiota could also be proposed
as a biomarker of yogurt intake. Such changes could
happen either directly, with the survival of S. thermophi-
lus and L. bulgaricus in the host’s GIT after yogurt in-
take, or indirectly, through modification of the existing
microbiota. S. thermophilus and L. bulgaricus have
non-human origins and low abilities to survive in gastric
juice and adhere to intestinal epithelial cells [116, 117].
Therefore, their presence in the host’s microbiota highly
relies on environmental exposure, in particular, the diet.
The survival and growth of S. thermophilus and L. bul-
garicus into the GIT has been confirmed by Burton et al.
[118], Mater et al. [119] and Elli et al. [117] who recov-
ered both strains from the faeces of healthy volunteers
after daily yogurt intake during 14, 12 and 7 days, re-
spectively. However, S. thermophilus and L. bulgaricus
are widely used by the fermented food industry, com-
promising their specificity. Semi-hard cheeses such as
Emmental and Gruyere or hard Italian varieties require
the use of thermophilic starter cultures including S. ther-
mophilus [120] and L. bulgaricus is used for mozzarella,
provolone, Parmesan, Romano and Swiss cheeses pro-
ductions. Therefore, the presence of these bacterial spe-
cies in human’ faeces does not necessarily indicate
yogurt intake.
Other groups of studies showed significantly increased
levels of non-starter bacterial strain after the consump-
tion of yogurt. Bartram and colleagues [121] reported an
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during 3 weeks of yogurt enriched with Bifidobacterium
longum and lactulose as well as after consumption by 12
healthy volunteers of a conventional yogurt in a
double-blind randomized crossover study. Similarly,
Hussein et al. [122] showed an increase in bifidobacterial
and lactobacilli populations after daily consumption by
28 male volunteers during 3 weeks of a regular yogurt in
a parallel study. Finally, Burton et al. [118] reported an
increased in faecal Bifidobacteria after consumption dur-
ing 2 weeks of a non-fermented milk acidified with
D-(+)-glucono-δ-lactone but not after the consumption
of yoghurt. In this field, it is, however, important to keep
in mind that there are different methods and no stand-
ard protocols for assessing bacterial proportions in faecal
samples [123].
Although the compounds mentioned in this section
have been linked to yogurt consumption, none of them
qualify as a biomarker of yogurt intake; these metabolites
are widely distributed in several food sources, compromis-
ing their specificity with respect to yogurt intake. These
compounds can more likely be used as biomarkers of nu-
trient intake, nutritional status or microbiota integrity
than as biomarkers of specific food consumption, as re-
cently reviewed by Holen and co-workers [123].
Biomarkers of eggs and processed eggs
From the initial systematic literature review process, a
total of 635 papers on egg intervention and egg con-
sumption were found. From these, 507 papers remained
after combining the results and removing duplicates.
After a careful reading and review of the collected litera-
ture, only 30 articles were found to be relevant. How-
ever, 6 articles were excluded because the dietary egg
was not the primary aim of the intervention. On the
other hand, 5 additional papers were found in the sec-
ondary literature search. From this set of 29 articles, 13
focused on “enriched eggs”, which were not included in
the table of potential biomarkers since our focus was on
biomarkers of regular eggs. At the end of this selection
process, 16 papers were further evaluated in searching
for useful biomarkers of egg intake (Additional file 1:
Table S9). However, no promising candidates were found
for egg consumption; therefore none of the metabolites
presented in Additional file 1: Table S9 was tabulated as
a candidate BFI in the main body of this review.
Eggs and processed eggs
Eggs are widely acknowledged as an excellent source of
high-quality protein, providing the richest mix of essential
amino acids, vitamins and minerals [124]. Eggs are among
the richest sources of dietary cholesterol. However, the rela-
tively high abundance of cholesterol in eggs has limited
their consumption. Although dietary recommendations foregg intake are often based on their cholesterol content, the
absorption efficiency of dietary cholesterol has been shown
to be highly variable between individuals (from 15 to 85%)
[125]. In contrast to cholesterol, which is colourless and
animal-derived, the carotenoids lutein and zeaxanthin are
plant-derived pigments that confer yellow, orange and red
colours to the egg yolk. Such compounds are also present
in fruits and vegetables, such as corn, kale, leeks, peas, let-
tuce, carrots, broccoli, basil and parsley [126, 127], and
their presence in eggs reflects the presence of plant prod-
ucts in the hens’ diet, as birds are not able to synthesize
them. Although the content of these compounds is higher
in plants than in eggs, egg-derived carotenoids are signifi-
cantly more bioavailable than those found in lutein-rich
vegetables, such as spinach [128].Whole eggs, egg yolk and egg by-products
Early studies showed that egg consumption was associated
with increased levels of low density lipoprotein (LDL) [129,
130]. LDL is the major carrier of dietary cholesterol and
cholesterol esters in the human body. LDL (as well as other
lipoprotein) measurements therefore provide the best
measure of cholesterol intake. Egg yolk contains significant
amounts of cholesterol, and Beynen et al. [131] measured
increased levels of both LDL and high-density lipoprotein
(HDL) in subjects who followed a diet rich in egg yolk (6
egg yolks/day for 10 days). Dietary cholesterol accounts for
approximately one third of the pooled body cholesterol, the
remaining being synthesized in the body [132]. In line with
this fact, modest increases in plasma lipoprotein profiles
were observed in two other studies [133, 134]. It is import-
ant to note that the majority of these early studies used un-
realistically large amounts of eggs. Later studies, using a
more realistic number of eggs, found an increase in plasma
LDL as well as HDL [135–138]. However, the LDL/HDL
ratio, an important risk factor for coronary heart disease,
was not changed [135]. Because cholesterol and cholesterol
esters are present in many other foods, including shellfish,
red meat, fish, milk, cheese and butter [139, 140], plasma
cholesterol (i.e. LDL or HDL content) is not a specific and
sensitive biomarker for egg.
In addition to cholesterol, lutein and zeaxanthin have
also been investigated as BFIs for egg consumption. In
several crossover studies, both molecules showed signifi-
cant increases in plasma [141, 142] and the macular ret-
ina [143]. Several independent crossover studies also
found increases in serum lutein and zeaxanthin after egg
consumption [144–146]. The authors also suggested a
relationship between lipoprotein and lutein levels after
finding that egg consumption increased the concentra-
tion of HDL and LDL particles containing lutein and ze-
axanthin [145, 146]. However, lutein and zeaxanthin
cannot be viewed as specific biomarkers of egg intake
Münger et al. Genes & Nutrition  (2018) 13:26 Page 13 of 18since they are also present in many vegetable sources,
such as corn, carrots, peppers and green leafy vegetables.
Enriched eggs
Eggs are increasingly being enriched to contain higher
levels of key health-promoting nutrients such as omega 3
(ω-3) fatty acids, including alpha-linolenic acid (ALA),
docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA). Enrichment has also been extended to lutein, lyco-
pene, vitamin E and selenium. Egg enrichment is obtained
by modifying the hen’s diet to incorporate the target nutri-
ent or precursors thereof. In many cases, this is done by
feeding hens flaxseeds [147].
Consumption of lutein-enriched eggs has shown in-
creased levels of lutein in human plasma [128, 148, 149].
A number of studies have employed DHA-enriched eggs
and tracked the prevalence of DHA in plasma [150]. On
the other hand, two studies utilizing ALA-enriched eggs
found no correlation between ALA levels in the blood
and the levels of egg consumption. Instead, a marked in-
crease in DHA was observed [147] along with increased
total triglycerides [151].
One of the first studies to use ω-3-enriched eggs
showed that ω-3 fatty acids were significantly enriched
in breast milk upon consumption of two ω-3-enriched
eggs for 6 weeks [152]. Furthermore, this intervention
did not alter plasma cholesterol nor plasma triglyceride
levels. A similar effect was seen in two other studies in
which EPA [153] and DHA [153, 154] were significantly
increased. Conversely, other studies on ω-3 enriched
eggs found a reduction in triglyceride levels [155]. Inter-
estingly, a more recent study did not observe any in-
crease in ω-3 fatty acids [156].
In conclusion, egg consumption and their effects on
plasma composition have been studied for many years.
Early studies of egg intake largely evaluated dietary choles-
terol. Although eggs are a rich source of cholesterol, other
animal sources contain cholesterol as well. Thus, plasma
cholesterol and plasma LDL/HDL levels are not useful
biomarkers of egg intake. Most recent studies have
switched from evaluating plasma cholesterol content to
evaluating the presence of molecules such as carotenoids.
However, carotenoids cannot be considered as specific
biomarkers of egg intake since they are also present in
many vegetable sources. While enriched eggs contain rela-
tively high amounts of low abundance micronutrients, the
use of these molecules as BFIs should not be considered
as general biomarkers for the intake of eggs or enriched
eggs. To date, a sensitive and specific biomarker of egg
consumption has not yet been reported in the literature.
Conclusions
Gao et al. [2] describe three major classes of dietary and
health biomarkers: (i) exposure and intake biomarkersreflecting the level of extrinsic variables that humans are
exposed to; (ii) effect biomarkers referring to the func-
tional response of the human body to an exposure; (iii)
susceptibility biomarkers representing the individual re-
silience to an exposure. BFIs belong to the first class of
biomarkers and their applications depend on their kin-
etic behaviour. Short term markers (e.g. galactonate for
dairy products) reflect recent intake and can be used to
assess the validity of dietary assessment methods such as
24 h recall or food diaries and multiple assessments can
be used to assess habitual diet. On the other hand,
long-term intake (e.g. C15:0 for dairy products) reflect
habitual intake. Gao et al. [2] propose a flexible defin-
ition of biomarkers, their classification depending on the
intended use. In that regard, some of the candidate BFIs
described in this review might also be interesting suscep-
tibility or effect biomarker useful to link disease risk to
habitual diet.
However, although many compounds have been associ-
ated with the intake of dairy or egg products, no reliable
biomarkers have been identified so far and the candidate
markers reported in this review (Table 1) need further in-
vestigation since validation criteria were not fully fulfilled
by any of them (Table 2). Table 2 highlights the aspects
which still need to be clarified or investigated to fully val-
idate the proposed biomarkers. Lipids such as C17:0,
C:15:0, C17:1 and myristoyl-sphingomyelin as well as a
galactose metabolite (galactonate) are the most promising
candidates for dairy products in general, methyl palmitate
for butter and amino acid derivatives for cheese (Table 1).
Instead, for milk, milk proteins and fermented dairy prod-
ucts, including yogurt, the evidence for potentially inter-
esting BFIs is scarce.
The identification of BFIs for dairy products is quite
challenging, as this food group is characterized by mar-
keted products with a highly heterogeneous composition
resulting from differences in processing (e.g. fermentation,
starter cultures, storage conditions and fat content), as
well as in the quality of the milk used as raw material (sea-
son, feeding process, stage of lactation, region). Moreover,
the candidate markers may originate from external
sources, including the plants on which the animals are
fed, so that these markers may also be found in meat and
meat products. Therefore, the reliable marker should be
sufficiently robust and specific to discriminate among dif-
ferent foods of animal origin. The candidate markers sum-
marized in this review derive from particular compounds
present in foods of animal origin (e.g. ruminant fatty
acids) or resulting from food processing (e.g. cyclic dipep-
tides for hydrolyzed whey protein). The validation scheme
shown in Table 2 clearly shows that none of these markers
are specific enough for the individual food investigated
(question 1). However, a combination of markers, which
reflect different characteristics of the food of interest (e.g.
Münger et al. Genes & Nutrition  (2018) 13:26 Page 14 of 18fat content, food processing, animal feeding, etc.) could
provide a better estimation of dairy intake. Moreover, the
results of the literature search pointed out that the num-
ber of studies investigating a specific class of dairy prod-
ucts (e.g. cheese, milk or yogurt) is quite limited
(Additional file 1: Tables S3–S8) and information regard-
ing quantitative aspects and kinetic is lacking (questions 2
and 3, respectively). Intervention studies based on untar-
geted approaches should also be designed in order to
evaluate the sensitivity and specificity of markers, which
are able to discriminate among different dairy products,
particularly among different fermented products (e.g.
cheese and yogurt or different varieties of cheese), be-
tween butter and other high-fat dairy products, as well as
between dairies and other ruminant foods. Moreover, the
heterogeneity in these foods may invalidate their use as
universal markers for different situations, e.g. for popula-
tions in different geographical areas. Therefore, further
studies should test the candidate biomarkers for dairy in-
take in different populations (question 4).
As for dairy products, sensitive and specific biomarkers
for egg consumption have not yet been reported. The
studies evaluated in this review focused on compounds
(cholesterol and carotenoids) targeted because of their
functional properties, rather than their potential as BFIs.
Also, untargeted metabolomics approaches have not been
carried out so far. Moreover, the targeted studies revealed
that the nutritional content of eggs is highly influenced by
the animal’s diet, what represents a source of variation
that needs to be taken into account in further investiga-
tions. Acute untargeted and pharmacokinetic studies are
therefore needed to identify suitable, specific and sensitive
biomarkers of egg and egg-derived product intake.
Finally, both for dairy products and egg products,
blood (plasma or serum) was the main biological sample
investigated; new studies should therefore address other
matrices, in particular, urine.
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